secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2026-08-28T14:31:00+00:00
Accession:  0001104659-26-102917
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin reports positive QRX003 interim data, raises up to $50M in private placement
--------------------------------------------------------------------------------

- Private placement up to $50M: $30.8M upfront at $4.88/ADS+warrant, 6,305,300 ADSs and warrants for 3,152,650 ADSs.
- Net proceeds ~$29M at Aug 31 close; funds into 2H 2029; proceeds for QRX003 development and general corporate.
- Phase 2/3 CL-QRX003-004: 4/6 (66.7%) met primary endpoint (≥1-grade IGA improvement), p=0.0087 vs α=0.0215.
- Secondary GIC endpoint significant (p=0.007); no treatment-related SAEs; recruitment done by end 2026, topline 2Q 2027.
- Exchange agreements: issued 222,574 ADSs to settle ~$1.146M accrued interest on 2020 notes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926102917/0001104659-26-102917-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926102917/tm2624258d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-102917

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer